A convergent trend across gastric, ovarian, breast, liver, and lung oncology is the maturation of cell-free DNA (cfDNA)-based liquid biopsy platforms that exploit methylation patterns, fragmentomics, and mutational signatures as noninvasive surrogates for tissue biopsy. Tools like MethylScan, the GCML-score, cfMeDIP-seq-derived breast cancer signatures, and stacked machine learning frameworks for ovarian cancer all share a common architecture: large, multi-site training cohorts feeding into internally and externally validated models that report AUCs consistently above 0.95. This rigorous train/validate/externally-validate pipeline—exemplified by GCML-score's 13 differentially methylated regions and the multi-omics whole-genome cfDNA assay's fragmentomic-mutational integration—has become the de facto standard for demonstrating clinical-grade diagnostic performance and generalizability across independent populations, including the China cohort for ovarian cancer and multi-center cohorts for gastric cancer.
Mechanistically, these platforms exploit tumor-specific epigenetic dysregulation (differential methylation), nucleosome-driven fragmentation patterns, and somatic mutational signatures shed into circulation, allowing a single blood draw to substitute for or complement invasive tissue biopsy, low-dose CT, and endoscopic screening. Beyond binary cancer detection, this biology supports finer clinical tasks: GCML-score's dynamic tracking of tumor burden during neoadjuvant chemotherapy, cfDNA methylation signatures' noninvasive classification of estrogen receptor status in breast cancer, and machine learning frameworks incorporating serum biomarkers like HE4 for pre-operative risk stratification in ovarian cancer. This signals a trajectory from simple "cancer yes/no" screening toward multi-dimensional molecular phenotyping—staging, subtyping, and treatment-response monitoring—all from plasma.
The field is also consolidating toward multicancer detection panels (MethylScan spanning liver, lung, ovarian, and stomach cancers) and organ-specific high-performance assays (HelioLiver Dx for hepatocellular carcinoma surveillance in high-risk populations), reflecting a shift from single-cancer LDCT- or endoscopy-based screening paradigms toward centralized, cost-effective, blood-based population screening infrastructure. Consistent performance across histological subtypes and disease stages (e.g., lung cancer assay equivalence across stages) further supports clinical scalability. Collectively, these trends point toward liquid biopsy becoming a primary modality not only for early detection but for longitudinal disease monitoring and therapeutic decision-making, progressively displacing or supplementing traditional imaging and invasive tissue sampling across the cancer care continuum.